C023P: Avelumab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade avelumab biosimilar specifically binds to the programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by avelumab.C003P: Semaglutide Biosimilar
Source: The recombinant peptide semaglutide biosimilar was produced in the semaglutide stable cell line.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by semaglutide.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.C003P: Liraglutide Biosimilar
Source: The recombinant peptide liraglutide biosimilar was produced in the liraglutide stable cell line.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by liraglutide.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.C072P: Envafolimab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant humanized nanobody (VHH-hIgG1 Fc fusion protein) .
Specificity/Sensitivity: The in vivo grade envafolimab specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by envafolimab.C009P: Trastuzumab Biosimilar, HER2/ErbB-2/c-neu Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody trastuzumab biosimilar specifically binds to the human HER2 / ErbB-2 / c-neu.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by trastuzumab.C013P: Aflibercept Biosimilar
Recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1).
Specificity/Sensitivity: The aflibercept biosimilar protein specifically binds to the human VEGF.
Applications: Functional assays, and those assays for studying biological pathways affected by aflibercept.C034P: Secukinumab Biosimilar, Human IL17A Monoclonal Antibody
Recombinant fully human IgG1 monoclonal antibody.
Specificity/Sensitivity: The monoclonal antibody Secukinumab biosimilar specifically binds to the human IL17A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Secukinumab.C061P: Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody
Recombinant Human IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody ramucirumab biosimilar specifically binds to the human VEGFR2 (KDR).
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ramucirumab.C032P: Tocilizumab Biosimilar, Anti-Human IL-6R Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade tocilizumab biosimilar specifically binds to the human interleukin-6 receptor (IL-6R).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tocilizumab.C071P: Sacituzumab Biosimilar, Human Trop-2 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody sacituzumab biosimilar specifically binds to the human Trop-2 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by sacituzumab.